KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas

摘要: Alexander R E, Lopez-Beltran A, Montironi R, MacLennan G T, Post K M, Bilbo S Jones T D, Huang W, Rao Q, Sen J Meehan K, Cornwell Miravalle L & Cheng (2012) Histopathology KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas Aims:  To determine whether mutations occur adenocarcinoma. Methods and results:  Twenty-six cases adenocarcinoma were analysed. DNA was extracted from formalin-fixed, paraffin-embedded tissue amplified with shifted termination assay technology, which recognizes wild-type or mutant target sequences selectively extends detection primers labelled nucleotides. A found three (11.5%) 26 adenocarcinomas. Two these exhibited G13D mutation, whereas the remaining case contained G12V. None ten urothelial carcinoma glandular differentiation displayed mutation. Colonic 18 (33%) 55 cases. There no distinct difference regard to grade, stage outcome according limited clinicopathological data available. However, two youngest patients, aged 32 39 years, our study group, mean population age 61 years, have KRAS. Conclusions:  are Future clinical trials for treatment adenocarcinoma, employing targeted therapies similar those used colon cancer, may also benefit predictive implications mutational testing.